BIENERTOVÁ VAŠKŮ, Julie, Ota HLINOMAZ and Anna VAŠKŮ. Are common leptin promoter polymorphisms associated with restenosis after coronary stenting? Heart Vessels. Japan: Springer Japan, 2007, vol. 2007, 22(5), p. 310-5, 6 pp. ISSN 0910-8327.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Are common leptin promoter polymorphisms associated with restenosis after coronary stenting?
Name in Czech Jsou v populaci časté polymorfismy v genu pro leptin asociovány s výskytem restenózy po implantaci stentu?
Authors BIENERTOVÁ VAŠKŮ, Julie (203 Czech Republic, guarantor), Ota HLINOMAZ (203 Czech Republic) and Anna VAŠKŮ (203 Czech Republic).
Edition Heart Vessels, Japan, Springer Japan, 2007, 0910-8327.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Japan
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.043
RIV identification code RIV/00216224:14110/07:00022111
Organization unit Faculty of Medicine
UT WoS 000249624100004
Keywords in English leptin; restenosis; gene; polymorphism
Tags gene, leptin, polymorphism, restenosis
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Julie Dobrovolná, Ph.D., učo 4805. Changed: 1/7/2008 09:52.
Abstract
The hypertrophy of vascular smooth muscle cells as well as neointimal proliferation is critical in vascular remodeling, whereas leptin has proved to play an important role recently. The aim of the study was to investigate possible associations of two common leptin gene polymorphisms with restenosis after percutaneous coronary intervention (PCI). To study the association of two promoter polymorphisms, LEP 2548 G/A and LEP 188 C/A (dbSNP ID rs7799039 and rs791620) with neointimal proliferation in humans, 98 consecutive patients undergoing stenting into small coronary arteries (<3 mm) were genotyped. After a 6 month follow up, the restenosis rate was estimated. Restenosis >50% occurred in 33.3% of patients carrying both A alleles, 33.3% of carriers of A and C alleles, and 31.4% of carriers of two CC alleles of LEP 188 C/A polymorphism; and in 25.0% of patients with AA, 32.7% with AG, and 30.4% with GG genotype of LEP 2548 G/A polymorphism. Interestingly, the heterozygote AG genotype of LEP 2548 polymorphism represented a highly signifi cant risk for multiple vessel disease when compared to both homozygote genotypes AA/GG (odds ratio = 4.038, 95% confidence interval: 1.732 to 9.465, Pcorr = 0.001). Based on our findings, the AG genotype of LEP 2548 G/A polymorphism might be considered a genetic marker for multiple vessel disease but not for restenosis after PCI. The role of the leptin gene polymorphisms as genetic markers of restenosis will require further investigation to elucidate the underlying pathophysiological consequences.
Abstract (in Czech)
Hypetrofie hladkých svalových buněk společně s neointimální proliferací představují klíčové faktory v cévní remodelaci, kde se leptin uplatňuje jako významný regulátor. Cílem této studie bylo prozkoumat možný vztah dvou v populaci četných polymorfismů v genu pro leptin (dbSNP ID rs7799039 a rs791620)s výskytem restenózy po implantaci stentu u českých pacientů s onemocněním koronárních tepen. Heterozygotní genotyp AG polymorfismu LEP 2548G/A přitom přinášel 4x vyšší riziko postižení více než jedné koronární arterie než ostatní varianty (odds ratio = 4.038, 95% konfidenční interval: 1.732 až 9.465, Pcorr = 0.001). Role genetické variability v genu pro leptin jako genetických markerů restenózy bezesporu vyžaduje další zkoumání na větších populačních vzorcích.
Links
MSM 141100002, plan (intention)Name: Molekulární patofyziologie multigenních chorob
Investor: Ministry of Education, Youth and Sports of the CR, Molecular pathophysiology of multigene diseases
PrintDisplayed: 30/4/2024 12:51